1. Home
  2. INLF vs SCYX Comparison

INLF vs SCYX Comparison

Compare INLF & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

INLF

INLIF LIMITED

N/A

Current Price

$4.13

Market Cap

59.6M

Sector

Industrials

ML Signal

N/A

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$0.69

Market Cap

60.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INLF
SCYX
Founded
2016
1999
Country
China
United States
Employees
156
29
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
59.6M
60.4M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
INLF
SCYX
Price
$4.13
$0.69
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
21.9K
338.4K
Earning Date
03-06-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
61.36
EPS
N/A
N/A
Revenue
N/A
$257,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$608.78
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.24
$0.57
52 Week High
$5.20
$1.29

Technical Indicators

Market Signals
Indicator
INLF
SCYX
Relative Strength Index (RSI) 63.70 27.80
Support Level $0.50 $0.57
Resistance Level $4.69 $0.70
Average True Range (ATR) 0.38 0.06
MACD -0.05 -0.03
Stochastic Oscillator 66.37 4.22

Price Performance

Historical Comparison
INLF
SCYX

About INLF INLIF LIMITED

INLIF Ltd, through its subsidiary, is engaged in the research, development, manufacturing, and sales of injection molding machine-dedicated manipulator arms. In addition, it offers installation and warranty services for manipulator arms, and accessories and raw materials for manipulator arms. Its portfolio includes injection molding machine-dedicated manipulator arms, including transverse single and double-axis manipulator arms, transverse and longitudinal multi-axis manipulator arms, and large bullhead multi-axis manipulator arms.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: